11 Stocks Most Likely to See a Short Squeeze RallySchaeffers Research · Oct 12, 2026
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual MeetingBusiness Wire · Oct 6, 2026
Dyadic International (NASDAQ:DYAI) & Amylyx Pharmaceuticals (NASDAQ:AMLX) Critical ReviewDefense World · Oct 4, 2026
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH TreatmentMarketBeat · Oct 3, 2026
10 Stocks With Massive Short Squeeze PotentialSchaeffers Research · Oct 1, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 16, 2026Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.36 | -$0.39 | Miss |
| May 7, 2026 | -$0.34 | -$0.37 | Miss |
| Mar 3, 2026 | -$0.31 | -$0.30 | Beat |
| Nov 6, 2025 | -$0.43 | -$0.37 | Beat |
| Aug 7, 2025 | -$0.44 | -$0.46 | Miss |
| May 8, 2025 | -$0.45 | -$0.42 | Beat |